Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LP.8.1-adapted mRNA COVID-19 vaccine
- Development stage
- Approved
- Lead developer
- BioNTech
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The LP.8.1-adapted mRNA COVID-19 vaccine is a monovalent vaccine developed by Pfizer and BioNTech, marketed under the brand name COMIRNATY as the 2025-2026 Formula. It utilizes modified RNA (modRNA) technology to encode the spike (S) glycoprotein of the SARS-CoV-2 Omicron sublineage LP.8.1, a descendant of the JN.1 variant. The vaccine is FDA-approved for active immunization to prevent COVID-19 in adults aged 65 and older and individuals aged 5 to 64 who are at high risk for severe outcomes. Administered via intramuscular injection, the vaccine leverages BioNTech's proprietary mRNA platform and Pfizer's manufacturing and regulatory infrastructure.
- Brand names
- COMIRNATY
- Other names
- LP.8.1-adapted mRNA COVID-19 vaccineCOMIRNATY (LP.8.1; COVID-19 Vaccine, mRNA)2025-2026 Formula COMIRNATYmonovalent LP.8.1 mRNA vaccine
02
Targets
SARS-CoV-2 spike
Beyond the preview
Go deeper on LP.8.1-adapted mRNA COVID-19 vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LP.8.1-adapted mRNA COVID-19 vaccine.